SG&A Expense Trends: Perrigo Company plc vs MorphoSys AG

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and MorphoSys AG from 2014 to 2023. Perrigo, a leader in over-the-counter health products, consistently outpaces MorphoSys, a biotech innovator, in SG&A spending. Over the decade, Perrigo's expenses grew by approximately 89%, peaking in 2023, while MorphoSys saw a staggering 860% increase, reflecting its aggressive expansion strategy. Notably, 2020 marked a pivotal year for MorphoSys, with expenses surging by 168% compared to 2019, highlighting its commitment to growth despite global economic challenges. This financial trajectory underscores the contrasting business models: Perrigo's steady market dominance versus MorphoSys's dynamic growth ambitions. As the industry continues to transform, these trends offer valuable insights into the strategic priorities of these pharmaceutical giants.